Premium
[O2–09–03]: PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR
Author(s) -
Lai Robert Y.K.,
Gordon Robert,
Chang MinKun,
Boyd Peter,
SavantLandry Ishani,
Aluri Jagadeesh,
Ino Mitsuhiro,
Horie Kanta,
Kotani Sadaharu,
Schuck Edgar L.,
Luthman Johan
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.194
Subject(s) - tolerability , pharmacokinetics , pharmacodynamics , cmax , medicine , placebo , pharmacology , dosing , adverse effect , area under the curve , bioavailability , pathology , alternative medicine